HCC ClinicalImpact: Expert Tools and Guidance to Apply the Results of Practice-Changing Clinical Research to Patient Care

Get expert insights into optimal care of patients with advanced HCC with expert commentaries, an interactive text module, downloadable slides, a treatment algorithm and toxicity resource, and an interactive treatment decision support tool.
Lipika Goyal, MD
Amit G. Singal, MD, MS


With atezolizumab plus bevacizumab becoming a standard of care for first-line systemic treatment of patients with advanced HCC, second-line therapy for these patients has become more challenging. In this commentary, expert faculty discuss treatment options in this setting.

Lipika Goyal, MD Amit G. Singal, MD, MS Released: October 1, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Genentech, a member of the Roche Group

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.